

Resource Summary Report

Generated by [dkNET](#) on Sep 3, 2026

LNCaP

RRID:CVCL_0395

Type: Cell Line

Proper Citation

RRID:CVCL_0395

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0395

Proper Citation: RRID:CVCL_0395

Description: Cell line LNCaP is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Prostate carcinoma

Defining Citation: [PMID:2734981](#), [PMID:3335022](#), [PMID:3518877](#), [PMID:6831420](#), [PMID:8687134](#), [PMID:9018337](#), [PMID:9090379](#), [PMID:9460501](#), [PMID:10702678](#), [PMID:10972993](#), [PMID:11135431](#), [PMID:11172901](#), [PMID:11304728](#), [PMID:11414198](#), [PMID:11416159](#), [PMID:12606952](#), [PMID:12725112](#), [PMID:14518029](#), [PMID:15162376](#), [PMID:15486987](#), [PMID:22213130](#), [PMID:22278370](#), [PMID:23671654](#), [PMID:24587179](#), [PMID:24618588](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26256267](#), [PMID:26589293](#), [PMID:26972028](#), [PMID:27036029](#), [PMID:27141528](#), [PMID:29194687](#), [PMID:29233929](#), [PMID:29660373](#), [PMID:29739788](#), [PMID:30787054](#), [PMID:35502546](#), [PMID:38892296](#)

Comments: Population: Caucasian., Part of: ENCODE project common cell types; tier 3., Group: Space-flown cell line (cellonaut).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: LNCaP

Synonyms: LNCAP, LNCap, Ln-Cap, LNCaP-RPCI, Lymph Node Carcinoma of the prostate

Cross References: BTO:BTO_0001321, CLO:CLO_0007365, CLO:CLO_0037116, EFO:EFO_0002071, MCCL:MCC:0000290, CLDB:cl3243, ArrayExpress:E-MTAB-2706,

BioGRID_ORCS_Cell_line:182, BioSample:SAMN03472386, cancercellines:CVCL_0395, CCRID:1101HUM-PUMC000040, CCTCC:GDC0283, CCTCC:GDC0284, ChEMBL-Cells:ChEMBL3307965, ChEMBL-Targets:ChEMBL612518, CLS:300265, Cosmic:704848, Cosmic:721368, Cosmic:721555, Cosmic:755298, Cosmic:759895, Cosmic:801348, Cosmic:850413, Cosmic:850745, Cosmic:850821, Cosmic:869155, Cosmic:918500, Cosmic:920967, Cosmic:921047, Cosmic:922553, Cosmic:923955, Cosmic:943176, Cosmic:948076, Cosmic:949248, Cosmic:1028648, Cosmic:1028701, Cosmic:1066237, Cosmic:1070886, Cosmic:1071481, Cosmic:1071906, Cosmic:1075275, Cosmic:1172626, Cosmic:1176618, Cosmic:1330909, Cosmic:1556120, Cosmic:1689708, Cosmic:1995486, Cosmic:2537792, Cosmic:2580128, Cosmic:2585151, Cosmic:2585228, Cosmic:2621168, Cosmic:2651770, Cosmic:2669169, Cosmic:2816221, DSMZ:ACC-256, DSMZCellDive:ACC-256, EGA:EGAS00001000610, GEO:GSE99795, GEO:GSM91927, GEO:GSM142457, GEO:GSM142458, GEO:GSM383948, GEO:GSM383953, GEO:GSM482669, GEO:GSM525800, GEO:GSM784790, GEO:GSM816634, GEO:GSM816637, GEO:GSM844579, GEO:GSM945240, GEO:GSM945282, GEO:GSM1022672, GEO:GSM1029460, GEO:GSM1029461, GEO:GSM1029462, GEO:GSM1029463, GEO:GSM1029464, GEO:GSM1029465, GEO:GSM1029466, GEO:GSM1029467, GEO:GSM1374622, GEO:GSM1374626, GEO:GSM2069518, GEO:GSM2069519, GEO:GSM2069520, GEO:GSM2069521, GEO:GSM2069522, GEO:GSM2069523, GEO:GSM2069524, GEO:GSM2069525, GEO:GSM2650017, GEO:GSM2650018, GEO:GSM2650019, GEO:GSM2650020, GEO:GSM2650021, GEO:GSM2650022, GEO:GSM3145602, GEO:GSM3145720, IARC_TP53:21076, LINCS_LDP:LCL-1298, Lonza:109, PharmacDB:LNCAP_850_2019, PRIDE:PXD000953, PRIDE:PXD000985, PRIDE:PXD002107, PRIDE:PXD002395, PRIDE:PXD003105, PRIDE:PXD003262, PRIDE:PXD006561, PRIDE:PXD032264, Progenetix:CVCL_0395, PubChem_Cell_line:CVCL_0395, TOKU-E:3599, Wikidata:Q6459234

ID: CVCL_0395

Record Creation Time: 20220427T220731+0000

Record Last Update: 20260829T234525+0000

Ratings and Alerts

No rating or validation information has been found for LNCaP.

No alerts have been found for LNCaP.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 3185 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Bernard MJ, et al. (2026) OGDHL Promotes Prostate Cancer Progression and Regulates Neuroendocrine Marker Expression and Nucleotide Abundance. *Molecular cancer research : MCR*, 24(5), 356.

Susa T, et al. (2026) Androgen Signaling Represses Homeobox C9, an Inhibitor of Androgen Receptor, in Prostate Cancer Cells. *International journal of molecular sciences*, 27(4).

Kim YN, et al. (2026) Phytochemical Profiling of the Halophyte *Artemisia fukudo* Makino and Its In Vitro Effects on Androgen-Related Pathways Associated With Benign Prostatic Hyperplasia and Alopecia. *ChemistryOpen*, 15(3), e202500481.

Sun R, et al. (2026) KDM5B-driven glucose metabolic reprogramming promotes enzalutamide resistance in prostate cancer via the lactate/hnRNPA1 lactylation/AR-V7 axis. *Molecular cancer*, 25(1).

Li Q, et al. (2026) Phase Separation of NFIB Suppresses SLC3A2-Mediated Ferroptosis in Castration-Resistant Prostate Cancer. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 13(26), e15340.

Wang Y, et al. (2026) GUTK induces apoptosis in reactivating quiescent prostate cancer cells via Aurora A-mediated stabilization of SOD2. *iScience*, 29(5), 115739.

Spickschen LFV, et al. (2026) Phosphinate or Urea? Synthesis and Biological Evaluation of Prostate Specific Membrane Antigen-Targeted Fluorophores With Different Zinc-Binding Motif. *ChemMedChem*, 21(10), e70320.

Al-Mathkour MM, et al. (2026) The YAP1 and EPHA3 receptor tyrosine kinase axis regulates cellular plasticity and treatment response. *Cellular signalling*, 141, 112368.

Cunningham ML, et al. (2026) PARP inhibitors elicit distinct transcriptional programs in homologous recombination competent castration-resistant prostate cancer. *Molecular oncology*, 20(2), 369.

Schober AS, et al. (2026) USP29-regulated noncanonical stabilization of the hypoxia-inducible factor-?? in aggressive prostate cancer. *Molecular oncology*.

Tsui M, et al. (2026) Landscape of Allele-Specific Expression in Prostate Cancer Reveals Recurrent, Stage-Specific Events in AR Signaling and Resistance Pathways. *Molecular cancer research : MCR*, 24(4), 242.

Ji Y, et al. (2026) Serotonin Modulates Lineage Plasticity in Neuroendocrine Prostate Cancer via Epigenetic Reprogramming. *Cancer discovery*, 16(4), 760.

Talmor B, et al. (2026) A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results. *Cancer research communications*, 6(3), 687.

Yang M, et al. (2026) MCCC2 stabilizes LTBP1 via suppressing SMURF1-dependent ubiquitination to drive bone metastasis in prostate cancer. *Oncogene*, 45(28), 2779.

Rosado-Sanz M, et al. (2026) Tumor-educated macrophages promote cytokine-driven lung colonization in triple-negative breast cancer. *Oncoimmunology*, 15(1), 2687381.

Watlington WK, et al. (2026) Inhibition of cyclin-dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation. *Molecular oncology*.

Kim M, et al. (2026) Bone Metastatic Progression of Prostate Cancer Is Regulated by TRIM28-LDHA-Mediated Metabolism. *Molecular cancer research : MCR*, 24(2), 93.

Nayak S, et al. (2026) Discovery of BMS-986365, a First-in-Class Dual Androgen Receptor Ligand-Directed Degradar and Antagonist, for the Treatment of Advanced Prostate Cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(1), 224.

Gumpert N, et al. (2026) Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer. *Cancer discovery*, 16(2), 250.

Baur??s M, et al. (2026) Targeting pre-existing club-like cells in prostate cancer potentiates androgen deprivation therapy. *EMBO molecular medicine*, 18(3), 943.